Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6831416 | 0.85 | NOD2 (0.48) | HSD11B1LIMK2MLYCDNOD2TRPM8 | |
| SCHEMBL16105694 | 0.84 | KMO (0.44) | LIMK2HDAC4HPGDALDH1A1LMNA | |
| SCHEMBL11238917 | 0.83 | PGR (0.46) | HSD11B1LIMK2MLYCDNOD2TRPM8 | |
| SCHEMBL26015707 | 0.83 | HSD11B1 (0.46) | HSD11B1LIMK2MLYCDNOD2TRPM8 | |
| SCHEMBL28307954 | 0.83 | PGR (0.46) | HSD11B1LIMK2MLYCDNOD2TRPM8 | |
| SCHEMBL11238921 | 0.83 | PGR (0.46) | HSD11B1LIMK2MLYCDNOD2TRPM8 | |
| SCHEMBL5646718 | 0.82 | LIMK2 (0.62) | HSD11B1LIMK2NOD2TRPM8ALDH1A1 | |
| SCHEMBL1223834 | 0.82 | PGR (0.58) | HSD11B1LIMK2MLYCDNOD2TRPM8 | |
| SCHEMBL10335922 | 0.82 | HSD11B1 (0.44) | HSD11B1LIMK2MLYCDNOD2TRPM8 | |
| SCHEMBL4503118 | 0.81 | CA1 (0.47) | LIMK2HDAC4HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230275272-A1 | ELECTROLYTES FOR ELECTROCHEMICAL ENERGY STORAGE | UCHICAGO ARGONNE, LLC (US) | 2023-08-31 | — | — | US | disclosed |
| US-8535560-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-8101612-B2 | N-3-isoxazolyl-4-methyl-3-(1-((1-methylethyl)oxy)-6-phthalazinyl)benzamide; p38 kinase inhibitor; antiinflammatory, analgesic agent; rheumatoid arthritis, osteoporosis, leukemia, psoriasis, Crohn's disease, rhinitis, ulcerative colitis, dermatitis, asthma, Alzheimer's disease, type I and II diabetes | AMGEN INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | UT-BATTELLE, LLC (US) | 2011-01-20 | — | — | US | disclosed |
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010115264-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HSD11B1 2455/4885LIMK2 1978/4885MLYCD 1540/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | HSD11B1 2201/4885LIMK2 1326/4885MLYCD 1878/4885 |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | HSD11B1 2719/4885LIMK2 1215/4885MLYCD 4671/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HSD11B1 1821/4885LIMK2 3117/4885MLYCD 1133/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | HSD11B1 1905/4885LIMK2 2724/4885MLYCD 1300/4885 |
| US-20230275272-A1 | ELECTROLYTES FOR ELECTROCHEMICAL ENERGY STORAGE | HCN2, SLC9A2, HCN3 | HSD11B1 965/4885LIMK2 3608/4885MLYCD 1206/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | HSD11B1 2704/4885LIMK2 444/4885MLYCD 2490/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885LIMK2 509/4885MLYCD 2021/4885 |
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | HSD11B1 1412/4885LIMK2 3465/4885MLYCD 2445/4885 |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | HSD11B1 1448/4885LIMK2 3352/4885MLYCD 3674/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885LIMK2 509/4885MLYCD 2021/4885 |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | POU2F1, POU2F2, POF1B | HSD11B1 3248/4885LIMK2 1541/4885MLYCD 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.